This phase 3 RCT evaluated once-daily oral orforglipron (6 mg, 12 mg, or 36 mg) vs placebo over 72 weeks in 238 Japanese adults with obesity disease (BMI 27–<35 kg/m² with ≥2 comorbidities, or BMI ≥35 kg/m² with ≥1 comorbidity), with co-primary endpoints of mean % bodyweight change and proportion achieving ≥5% bodyweight reduction.
At 72 weeks, mean bodyweight reductions were -5.9% (6 mg), -8.7% (12 mg), and -7.9% (36 mg) vs -0.6% with placebo (all p<0.0001); ≥5% bodyweight loss was achieved by 45.6%, 60.8%, and 58.8% of participants in the orforglipron groups, respectively, vs 15.2% with placebo.
Single-ethnicity (Japanese) sample limits generalizability; the trial included a relatively narrow BMI range aligned with Japanese regulatory definitions; no active comparator arm (e.g., semaglutide or tirzepatide) was included.
Oral orforglipron at all three doses produced clinically meaningful, statistically superior weight loss vs placebo in Japanese adults with obesity, with a gastrointestinal side-effect profile typical of GLP-1 receptor agonists; the 12 mg dose showed the greatest mean weight reduction (-8.7%).
Explore related topics